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ABSTRACT:
Objective: The aim of the study was to define pharmacodynamic markers for sudemycin D6, an experimental cancer drug that changes
alternative splicing in human blood.
Methods: Blood samples from 12 donors were incubated with sudemycin D6 for up to 24 hours, and at several time points total RNA from
lymphocytes was prepared and the pre-messenger RNA (mRNA) splicing patterns were analyzed with reverse transcription-polymerase
chain reaction.
Results: Similar to immortalized cells, blood lymphocytes change alternative splicing due to sudemycin D6 treatment. However, lymphocytes in blood respond slower than immortalized cultured cells.
Conclusions: Exon skipping in the DUSP11 and SRRM1 pre-mRNAs are pharmacodynamic markers for sudemycin D6 treatment and
show effects beginning at 9 hours after treatment.
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All human cells generate messenger RNA (mRNA) through
pre-mRNA splicing, a process that removes intervening
sequences (introns) and splices exonic sequences together
prior to their export into the cytosol.1 This process is conserved in all eukaryotic cells and performed by a multienzyme
complex, the spliceosome.2,3 Changes in alternative splicing
are a hallmark of cancer and targeting the spliceosome has
been proposed as a possible treatment for cancer.4,5

change certain alternative splicing patterns within 3 to 6 hours in
immortalized cells, possibly by causing a dissociation of the U2
complex.9
The aim of the study was to characterize RNA splicing biomarkers in primary human cells using an ex vivo assay we previously developed.10 We identified human RNA targets of
sudemycin D6 in human ex vivo blood samples that can be
used in future human clinical trials.

Sudemycins

Methods

Bacteria generate natural products that bind to components of
the spliceosome; 2 of the best-known examples are FR901464
and pladienolide, which causes selective regression of tumors in in
vivo cancer models,6,7 making them promising anticancer agents.
FR901464 is chemically unstable, and thus, more stable compounds were designed and optimized through focused medicinal
chemistry; these compounds are collectively called sudemycins.7,8
Sudemycins selectively stop the growth of tumors in mice and
preferably target cancer cells, sparing nonneoplastic cells through
an unknown mechanism.7 Similar to FR901464, sudemycins
bind to the U2 component SF3B1, which is part of the spliceosome.9 In cell culture, sudemycin D6 does not inhibit splicing but
*SRI Biosciences, 333 Ravenswood Avenue, Menlo Park, CA 94025,
USA.

An overview of the assay is shown in Figure 1.

Human subjects
Healthy volunteer blood donors were recruited in accordance with
the institutional review board protocol #15-0077, approved by the
University of Kentucky. To be included, subjects must be more than
18 years old, not on current chronic medication, and free from hepatitis. Blood was taken from healthy subjects in the morning after
an overnight fast to limit lipids that possibly interfered with the
RNA isolation. The intake of liquids was permitted.

Blood collection
About 30 mL of venous blood was collected in BD Vacutainer
vials (Becton, Dickinson, Franklin Lakes, NJ, USA) containing
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Figure 1. Overview of the assay. (A) Overall experimental design: patient
blood was drawn and citric acid and glucose were added. The treatment
with sudemycins is performed in blood storage bags for up to 24 hours,
followed by isolation of lymphocytes in Ficoll gradients, isolation of RNA,
and RT-PCR detection. (B) Chemical structure of sudemycin D6. RT-PCR
indicates reverse transcription-polymerase chain reaction.

acid citrate dextrose (“yellow cap”) solution A (trisodium citrate [22.0 g/L], citric acid [8.0 g/L], and dextrose [24.5 g/L]).
The blood samples were transferred from the Vacutainer vials
into 2 separate platelet storage bags (Blood Cell Storage, Inc.,
Seattle, WA, USA): 1 containing 18 mL of blood and the other
containing 12 mL of blood.

Ex vivo sudemycin treatment
The blood was treated with 1 µM sudemycin D6, dissolved in
dimethyl sulfoxide (DMSO) or an equal volume of DMSO in
the control. During the incubation time, 3-mL samples were
taken at 0, 3, 6, 9, and 24 hours.

Lymphocyte isolation
Lymphocytes from the samples were isolated using SigmaAldrich Accuspin System-Histopaque 1077 gradient tubes
(Sigma, St Louis, MO, USA), according to the manufacturer’s
protocol. After the isolation, lymphocytes were pelleted at
5000×g for 3 minutes.

RNA extraction
Total RNA was isolated from the pelleted lymphocytes using
TRIzol (Invitrogen, Waltham, MA, USA). About 1 mL of TRIzol
was added to the lymphocyte pellet and homogenized using a
1-mL pipette and incubated for at least 5 minutes. The aqueous
solution was isolated by adding 200 μL of chloroform/1 mL
TRIzol, separated by centrifugation at 12 000×g for 5 minutes.
RNA was precipitated using 500 µL isopropanol/1 mL original
TRIzol, washed with 75% ethanol, and resuspended in 25 µL water.
Reverse transcription-polymerase chain reaction was performed using 1 µg RNA and 1 pM reverse primer as previously
described.9 The primers (Table 1) are located in constitutive
exons flanking the alternative exons (Figure 1B).

Statistical Analysis

Gene expression signals were quantified using ImageJ11 and
relative quantities were determined by band intensities

within a lane. Exon inclusion was calculated by dividing the
intensity of the regulated gel band by the sum of both band
intensities. A Shapiro-Wilk test was used to determine the
normality for validity of the analysis of variance (ANOVA),
where P < .05 demonstrates a non normal distribution.12
The exon inclusion proportion was analyzed with an
ANOVA test and Tukey HSD (honest significant difference) post hoc13 using IBM SPSS Statistics treatments.14
Changes were considered significantly different with P < .05.
Subjects were separated by age, sex, and ethnicity and analyzed with paired t test and considered significantly different with P < .05.

Results
Selection of subjects
The blood donors were 21 to 51 years of age, 4 men, 8 women,
from different ethnicities (mean age = 31.75, median
age = 28) years (Table 2).

Assay
To test the effect of sudemycin D6 under in vivo conditions,
we treated whole blood samples ex vivo with sudemycin D6.
We used treatment conditions similar to blood banking,
which keeps cells intact for several days. Citric acid and glucose were added as an anticoagulant and nutrient, respectively, and the blood was stored in blood bags that allowed
gas exchange during the experiments. We did not observe
any hemolysis.

Changes in alternative splicing caused by sudemycin
D6 treatment
Sudemycin D6 is a compound that binds to the splicing
component SF3B1, which is part of the U2 small nuclear
ribonucleoprotein complex. We previously performed array
analyses and found that sudemycin D6 changes the usage of
numerous alternative splice sites at low µM concentrations
within hours in HeLa, RH19, and HEK293 cells.9 In most
cases, sudemycin causes exon skipping within 3 to 6 hours of
treatment. Importantly, these changes were reversible, ie, the
exon skipping was not detectable after 9 hours, which likely
reflects the inactivation of sudemycin D6 in aqueous solution.9 To identify biomarkers for possible sudemycin D6
clinical trials, we treated human blood samples ex vivo, using
the sudemycin D6 concentration of 1 µM that showed an
effect in cell culture. Because splice site selection can be
individual specific,15 we tested subjects from different ethnicities, both sexes and ages.
We tested 6 splicing events in the DUSP11, SRRM1,
RPp30, AURKB, MLH3, and PAPOLG genes (Figure 2A to F)
that showed high expression and reproducible changes in
RH19 and HEK293 cells.9 These findings were quantified by
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Table 1. Primers used.
Primer

Sequence

Amplicon size

DUSP 11 forward

5′-GAC ATC AAG TGC CTG ATG ATG A-3′

212, 151

DUSP11 reverse

5′-ATG TCC CCG GCA CCT ATT-3′

RPp30 forward

5′-TAT ATC TAG TGC TGC AGA AAG G-3′

RPp30 reverse

5′-GCC TAA AGA AAG TGG GGA TAA-3′

SRRM1 forward

5′-GAC TCT GGC TCC TCC TCC TC-3′

SRRM1 reverse

5′-GGA CTT CTC CTC CGT CTA CCA-3′

MLH3 forward

5′-TTA TTG CCT GTT TGA TGA GCA C-3′

MLH3 reverse

5′-TCC TTT GTT CCT CTG TCA CTG TT-3′

PAPOLG forward

5′-AAG AGA TCC CAT TCC CCA TC-3′

PAPOLG reverse

5′-TGC GTG ATG TAT CAA TAG TTG GA-3′

AURKB forward

5′-ATG ACC GGA GGA GGA TCT AC-3′

AURKB reverse

5′-GAT GGA CCT CCA GCT ACA AG-3′

193 (retained intron)

209, 167

220, 150

178, 112

182 (retained intron)

Table 2. Age and ethnicity of subjects.
Sample no.

Sex, self-identified ethnicity

Age

380

Female, white

21

657

Female, white

21

346

Female, Multi: African American and white

21

M.T.

Female, white

23

559

Female, white

24

278

Male, Hispanic/Latino

27

296

Female, white

29

786

Male, Asian

31

767

Male, white

44

944

Female, white

44

902

Female, African American

45

S.S.

Male, white

51

calculating the percent exon inclusion as the intensity of the
band containing the alternative exon divided by the intensity of
all bands (Figure 3A to F).
Our assay amplifies mRNA isoforms containing or skipping
an alternative exon using the same set of polymerase chain
reaction primers and is thus internally controlled.
DUSP11 and SRRM1 splicing patterns were changed in
all subjects beginning at 9 hours of treatment and did not
revert to the original splicing patterns after 24 hours, which
is in contrast to the splicing patterns in transformed cells
that revert to the pretreatment ratio at this time point.

Despite the small sample number, these changes were highly
significant (P values in a 1-way ANOVA: DUSP11: 9 hours:
P = 1.11 × 10−8; 24 hours: P = 6.27 × 10−13; SRRM1: 9 hours:
P = .00031; 24 hours: P = 1.47 × 10−9).
Although the splicing patterns for MLH3 and PAPOLG
showed a similar trend, the patterns varied between the various individuals. AURKB (12/12 cases) and RPp30 (11/12
cases) showed no changes in overall expression or alternative
splicing, respectively, in human blood samples, which is in
contrast to previous results in HEK293 and RH19 cells that
exhibit changes.

4
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Figure 2. Representative change of splicing patterns in tested genes. Shown are ethidium bromide–stained agarose gels after reverse transcriptionpolymerase chain reaction analysis. Numbers indicate the time of treatment with 1 µM sudemycin D6 in hours. M: 100-base pair marker, C: blood without
sudemycin but dimethyl sulfoxide for 24 hours in the blood bag. The amplicon sizes are given in Table 1, and the structure of the RNA products is
schematically indicated. (A) DUSP11, (B) SRRM1, (C) RPp30, (D) AURKB, (E) MLH3, and (F) PAPOLG.

Differences between sex, age, and ethnicity
There was no difference between the sexes and ethnicities.
However, unexpectedly, after 24 hours of sudemycin D6 treatment, samples from subjects older than 30 years showed a
lower percentage of exon inclusion than samples from subjects younger than 30 years in the PAPOLG gene, suggesting
that age modulates the response to sudemycin D6 (Figure 4).

Discussion

We were looking for a simple and robust assay to monitor
the effect of sudemycin D6 and possible future improved
sudemycins in primary human cells. Sudemycins have previously been shown to change splicing patterns in numerous

cell lines, including immortalized leukemia cell lines.16 As a
model for primary cells, we choose blood because it contains
a variety of cell types in a physiological environment. By
adding sudemycin to blood ex vivo, we could circumvent
clearance of the liver. Using the blood from 12 healthy
donors, we found that sudemycin D6 changes splice site
usage of the DUSP11 and SRRM1 pre-mRNA after 9 hours
of treatment. Our tested subjects showed statistically significant changes in the splicing patterns of DUSP11,
SRRM1, and PAPOLG. However, the degree of response was
variable for PAPOLG where older subjects showed a stronger
response to sudemycin. Alternative splicing patterns are frequently developmentally regulated1 and it has been reported
that some alternative splicing patterns are age dependent in
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Figure 3. Quantification of the changes in splicing. The band intensities of bands after reverse transcription-polymerase chain reaction and agarose gel
electrophoresis were determined by ImageJ and the percent exon inclusion was calculated as [intensity of alternative exon]/[sum of all exon intensities]. #
represents nonsignificant changes compared with 0-hour control (P > .05) and * represents significantly different group to 0-hour control (P ≤ .05). The
individual subjects are shown by different colors and referred to in Table 2. (A) DUSP11, (B) SRRM1, (C) RPp30, (D) AURKB, (E) MLH3, and (F) PAPOLG.
The changes in splicing were significant for the 9- and 24-hour time points when compared with dimethyl sulfoxide–treated controls:
DUSP11: 9 hours: P = 1.11 × 10−8; 24 hours: P = 6.27 × 10−13.
SRRM1: 9 hours: P = .00031; 24 hours: P = 1.47 × 10−9.
MLH3: 9 hours: P = 4.39 × 10−6; 24 hours: P = 9.00 × 10−11.
PAPOLG: 9 hours: P = .000017; 24 hours: P = 2.15 × 10−11.
AURKB: P = .78 (ns), RPp30: P = .43 (ns). ns indicates nonsignificant.

mature organisms,17 but this is the first report that shows
that age influences a splicing response to a drug.
The genes responding to sudemycin are likely merely indicators for a sudemycin D6 effect on splicing and are not causative for the death of cancer cells, as in most cases, they have
no known connection with disease. For example, DUSP11
(dual specific protein phosphatase) is a dual specificity protein phosphatase, removing phosphates from phosphoserine/
threonine and phosphotyrosine residues. DUSP11 binds
directly to RNA18 and changes in expression of the DUSP11
protein have been observed in inflammatory bowel disease.19
MLH3 is the MutL-Homolog 3 involved in DNA mismatch
repair, and rare polymorphisms of this gene are associated
with colorectal cancer.20,21

SRRM1 (serine and arginine repetitive matrix 1) promotes exon enhancer formation by interacting with serinearginine–rich proteins and has no known connection to a
disease,22 similar to RPp3023 that works in transfer RNA
maturation and PAPOLG (poly(A) polymerase gamma),
which is a poly(A) polymerase.24
There are differences between the response of cultured cells
and blood lymphocytes and cultured cells, as HeLa cells
change their splicing patterns after 2 to 4 hours in response to
sudemycin. Furthermore, in lymphocytes, there was no reversal of splicing up to 48 of treatment, whereas we saw the pretreatment splicing patterns in cultured cells after 24 hours. It is
likely that the transformation of the cells or the artificial culture conditions cause this difference.
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Figure 4. Comparison of sudemycin D6 response for PAPOLG in
different age groups. The relative splicing changes for PAPOLG
determined in Figure 3 were separated into subjects younger or older
than 30 years. Both groups show a statistically significant (P = .03)
difference in their response to sudemycin D6 treatment.

Limitations

Our study used ex vivo analysis in blood samples. Any treatment in humans will have to account for liver clearance of sudemycins. Despite highly significant changes (P = 6.27 × 10−13
and P = 1.47 × 10−9 for DUSP11 and SRRM1, respectively), the
number of subjects was only n = 12.

Conclusions

Changes in alternative splicing of DUSP11 and SRRM1 can be
used as biomarkers for sudemycin D6 treatment in human blood.
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